drugset / Trial / NCT01449266
Safety and Dialysability of Dotarem® in Dialysed Patients
NaSingle-groupOpen-label
Summary
To evaluate the dialysability of Dotarem®, after an IV injection of 0.1 mmol/kg in patients with chronic renal failure who require hemodialysis treatment.
Timeline
- Start
- 2011-11
- Primary completion
- 2012-03
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gadoterate meglumine | Diagnostic / imaging agent | 0.1 unknown | Intravenous |